Key points from article :
Viome, a preventive health company based in Bellevue, WA, has secured $25 million in a Series D round from investors including Khosla Ventures, Bold Capital, and Marc Benioff.
This funding will enable the company to establish a new diagnostics division focused on early detection of chronic diseases, addressing a significant gap in preventive healthcare. Viome’s approach combines advanced AI and the world’s largest gene expression database to offer home-based tests that provide users with personalised nutritional guidance. Their goal is to promote healthy aging by analysing epigenetic biomarkers and offering insights that support longevity.
Currently, fewer than 10% of Americans undergo regular screenings, and Viome aims to change that by expanding its diagnostic offerings. The company has already made strides in this area with its CancerDetect test for oral and throat cancer, which has achieved FDA Breakthrough Device Designation and boasts 90% sensitivity and 95% specificity. The new division will focus on developing further tests for conditions such as gut health, including irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD).
Viome’s diagnostics and personalised solutions aim to improve early detection and help millions lead healthier lives by addressing the growing demand for personalised healthcare. Their long-term vision is to shift healthcare from reactive to preventive, ultimately reducing the prevalence of chronic diseases and improving overall well-being.
